|
Principal
Applicant
|
Title
of Project
|
Funding
Source and Program
|
Years
of Tenure
|
|
M. Bernstein
Co-investigator
|
Neurobalstoma
screening in infancy in Quebec
|
The US National
Institute of Health/University of Minnesota (South Carolina Richmond
Hospital)
|
|
|
M. Bernstein
Chairmanship
|
POG New Agents
& Pharmacology Committee
|
The US National
Institute of Health
|
|
|
M. Bernstein
Principal Investigator
|
POG Phase I
Scientific Committee
|
The US National
Institute of Health
|
|
|
Dr. Claire Principal
Investigator
M. Bernstein
Co-investigator
|
Environment
and genetic polymorphisms in childhood acute lymphoblastic leukemia
|
MRC
|
2000-2003
|
|
Dr. Richard
Momparler Principal Investigator, M. Bernstein
Co-investigator
|
Inhibitors of
DNA methylation and histone deacetylase for therapy of leukemia
|
Leukemia Society
of America
|
2000-2003
|
|
M. Bernstein
Coordinator
|
Idarubicin pharmacokinetics
and accumulation of intracellular metabolites in leukemic cells
of children with multiply relapsed ALL, a section of POG 3160
|
Department of
oncology, McGill University/ Martinex
|
|
|
M. Bernstein
Co-investigator
|
A decision analysis
of current diagnostic management strategies in young febrile children
without evident bacterial focus of infection
|
|
|
M. Bernstein
Co-investigator
|
Pain control
for pediatric oncology procedures
|
In cooperation
with The Children’s Hospital of Eastern Ontario
|
|
M. Bernstein
Co-investigator
|
A Canadian multicenter
ITP trial
|
In cooperation
with the Toronto Hospital for Sick Children
|
|
C. Polychronakos
Principal Investigator,
M. Bernstein
Co-investigator
|
Parental Imprinting
of the insulin-like growth factor II (IGF2) and its receptor.
|
Montreal Children’s
Hospital
|
|
|
|
|
|
|
|
|
